Arzanforoosh Fatemeh, Croal Paula L, van Garderen Karin A, Smits Marion, Chappell Michael A, Warnert Esther A H
Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands.
Radiological Sciences, Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Front Oncol. 2021 Mar 23;11:648528. doi: 10.3389/fonc.2021.648528. eCollection 2021.
Relative cerebral blood volume (rCBV) is the most widely used parameter derived from DSC perfusion MR imaging for predicting brain tumor aggressiveness. However, accurate rCBV estimation is challenging in enhancing glioma, because of contrast agent extravasation through a disrupted blood-brain barrier (BBB), and even for nonenhancing glioma with an intact BBB, due to an elevated steady-state contrast agent concentration in the vasculature after first passage. In this study a thorough investigation of the effects of two different leakage correction algorithms on rCBV estimation for enhancing and nonenhancing tumors was conducted.
Two datasets were used retrospectively in this study: 1. A publicly available TCIA dataset (49 patients with 35 enhancing and 14 nonenhancing glioma); 2. A dataset acquired clinically at Erasmus MC (EMC, Rotterdam, NL) (47 patients with 20 enhancing and 27 nonenhancing glial brain lesions). The leakage correction algorithms investigated in this study were: a unidirectional model-based algorithm with flux of contrast agent from the intra- to the extravascular extracellular space (EES); and a bidirectional model-based algorithm additionally including flow from EES to the intravascular space.
In enhancing glioma, the estimated average contrast-enhanced tumor rCBV significantly (Bonferroni corrected Wilcoxon Signed Rank Test, p < 0.05) decreased across the patients when applying unidirectional and bidirectional correction: 4.00 ± 2.11 (uncorrected), 3.19 ± 1.65 (unidirectional), and 2.91 ± 1.55 (bidirectional) in TCIA dataset and 2.51 ± 1.3 (uncorrected), 1.72 ± 0.84 (unidirectional), and 1.59 ± 0.9 (bidirectional) in EMC dataset. In nonenhancing glioma, a significant but smaller difference in observed rCBV was found after application of both correction methods used in this study: 1.42 ± 0.60 (uncorrected), 1.28 ± 0.46 (unidirectional), and 1.24 ± 0.37 (bidirectional) in TCIA dataset and 0.91 ± 0.49 (uncorrected), 0.77 ± 0.37 (unidirectional), and 0.67 ± 0.34 (bidirectional) in EMC dataset.
Both leakage correction algorithms were found to change rCBV estimation with BBB disruption in enhancing glioma, and to a lesser degree in nonenhancing glioma. Stronger effects were found for bidirectional leakage correction than for unidirectional leakage correction.
相对脑血容量(rCBV)是从DSC灌注磁共振成像中得出的用于预测脑肿瘤侵袭性的最广泛使用的参数。然而,由于造影剂通过破坏的血脑屏障(BBB)外渗,在增强型胶质瘤中准确估计rCBV具有挑战性,甚至对于血脑屏障完整的非增强型胶质瘤也是如此,这是因为首次通过后血管系统中稳态造影剂浓度升高。在本研究中,对两种不同的渗漏校正算法对增强型和非增强型肿瘤rCBV估计的影响进行了全面研究。
本研究回顾性使用了两个数据集:1. 一个公开可用的TCIA数据集(49例患者,其中35例为增强型胶质瘤,14例为非增强型胶质瘤);2. 一个在伊拉斯谟医学中心(EMC,荷兰鹿特丹)临床获取的数据集(47例患者,其中20例为增强型胶质瘤,27例为非增强型脑胶质病变)。本研究中研究的渗漏校正算法为:一种基于单向模型的算法,造影剂从血管内流向血管外细胞外间隙(EES);以及一种基于双向模型的算法,另外包括从EES到血管内空间的流动。
在增强型胶质瘤中,应用单向和双向校正后,患者估计的平均对比增强肿瘤rCBV显著降低(Bonferroni校正的Wilcoxon符号秩检验,p < 0.05):在TCIA数据集中分别为4.00±2.11(未校正)、3.19±1.65(单向)和2.91±1.55(双向),在EMC数据集中分别为2.51±1.3(未校正)、1.72±0.84(单向)和1.59±0.9(双向)。在非增强型胶质瘤中,应用本研究中使用的两种校正方法后,观察到的rCBV存在显著但较小的差异:在TCIA数据集中分别为1.42±0.60(未校正)、1.28±0.46(单向)和1.24±0.37(双向),在EMC数据集中分别为0.91±0.49(未校正)、0.77±0.37(单向)和0.67±0.34(双向)。
发现两种渗漏校正算法均会改变增强型胶质瘤中血脑屏障破坏时的rCBV估计,在非增强型胶质瘤中影响程度较小。双向渗漏校正的效果比单向渗漏校正更强。